全文获取类型
收费全文 | 30292篇 |
免费 | 2253篇 |
国内免费 | 729篇 |
专业分类
耳鼻咽喉 | 61篇 |
儿科学 | 557篇 |
妇产科学 | 396篇 |
基础医学 | 2031篇 |
口腔科学 | 252篇 |
临床医学 | 3466篇 |
内科学 | 8076篇 |
皮肤病学 | 647篇 |
神经病学 | 1344篇 |
特种医学 | 617篇 |
外国民族医学 | 3篇 |
外科学 | 2517篇 |
综合类 | 2552篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 3001篇 |
眼科学 | 232篇 |
药学 | 5776篇 |
78篇 | |
中国医学 | 730篇 |
肿瘤学 | 935篇 |
出版年
2024年 | 112篇 |
2023年 | 933篇 |
2022年 | 1556篇 |
2021年 | 2051篇 |
2020年 | 1841篇 |
2019年 | 1819篇 |
2018年 | 1716篇 |
2017年 | 1370篇 |
2016年 | 1119篇 |
2015年 | 1144篇 |
2014年 | 2329篇 |
2013年 | 2332篇 |
2012年 | 1532篇 |
2011年 | 1712篇 |
2010年 | 1344篇 |
2009年 | 1237篇 |
2008年 | 1275篇 |
2007年 | 1080篇 |
2006年 | 828篇 |
2005年 | 717篇 |
2004年 | 584篇 |
2003年 | 549篇 |
2002年 | 383篇 |
2001年 | 336篇 |
2000年 | 264篇 |
1999年 | 228篇 |
1998年 | 163篇 |
1997年 | 177篇 |
1996年 | 153篇 |
1995年 | 139篇 |
1994年 | 124篇 |
1993年 | 131篇 |
1992年 | 119篇 |
1991年 | 130篇 |
1990年 | 105篇 |
1989年 | 87篇 |
1988年 | 89篇 |
1987年 | 77篇 |
1986年 | 71篇 |
1985年 | 107篇 |
1984年 | 151篇 |
1983年 | 131篇 |
1982年 | 114篇 |
1981年 | 143篇 |
1980年 | 93篇 |
1979年 | 104篇 |
1978年 | 95篇 |
1977年 | 87篇 |
1976年 | 83篇 |
1975年 | 79篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
《Journal of vascular and interventional radiology : JVIR》2022,33(4):359-367.e8
PurposeTo review and to compare indirectly the outcomes of minimally invasive therapies for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.Materials and MethodsA literature search via Medline and Cochrane Central databases was completed for randomized control studies published between January 2000 to April 2020 for the following therapies: Rezum, Urolift, Aquablation, and prostatic artery embolization (PAE). Data on the following variables were included: International prostate symptom score (IPSS), maximum urinary flow rate, quality of life, and postvoid residual (PVR). Standard mean differences between treatments were compared through a meta-analysis using transurethral resection of the prostate (TURP) to assess differences in treatment effect.ResultsThere was no significant difference in outcomes between therapies for IPSS at the 3, 6, and 12-month follow ups. Although outcomes for Rezum were only available out to 3 months, there were no consistently significant differences in outcomes when comparing Aquablation versus PAE versus Rezum. TURP PVR was significantly better than Urolift at 3, 6, and 12 months. No significant differences in minor or major adverse events were noted.ConclusionAlthough significant differences in outcomes were limited, Aquablation and PAE were the most durable at 12 months. PAE has been well studied on multiple randomized control trials with minimal adverse events while Aquablation has limited high quality data and has been associated with bleeding-related complications. 相似文献
4.
《Digestive and liver disease》2022,54(11):1486-1493
BackgroundCold snare polypectomy (CSP) is a promising technique for the removal of sessile serrated polyps (SSPs) ≥ 10 mm. However, the efficacy and safety of this technique remain undetermined.AimsWe aimed to comprehensively evaluate the efficacy and safety of CSP for SSPs ≥ 10 mm.MethodsPubMed, EMBASE, Web of Science and Cochrane Library were searched up to January 2021.ResultsA total of 10 studies consisting of 1727 SSPs (range, 10–40 mm) from 1021 patients were included. The overall rates of technical success, adverse events (AEs) and residual SSPs were 100%, 0.7% and 2.9%, respectively. Subgroup analysis showed that the rates of technical success and AEs were comparable between CSP and cold endoscopic mucosal resection (EMR) (99.9% vs. 100% and 1.3% vs. 0.5%, respectively), between the proximal and distal colon (100% vs. 99.9% and 0.3% vs. 0, respectively), and between polyps of 10–19 mm and ≥20 mm (99.8% vs. 100% and 0.9% vs. 0, respectively). However, subgroup analysis showed that the rate of residual SSPs was slightly lower in CSP compared with cold EMR (1.3% vs. 3.9%), as well as in polyps of 10–19 mm compared with those ≥20 mm (3.1% vs. 4.7%).ConclusionCSP was an effective and safe technique for removing SSPs ≥ 10 mm. 相似文献
5.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献
6.
Barouyr Baroudjian Dimitri Arangalage Stefania Cuzzubbo Baptiste Hervier Celeste Lebbé Gwenael Lorillon 《Expert review of anticancer therapy》2019,19(3):209-222
Introduction: Immune checkpoint inhibitors (ICI) are now a standard of care in the treatment of many cancers leading to durable responses in patients with metastatic disease. These agents are generally well tolerated but may lead to the occurrence of immune-related adverse events (irAEs). As any organ may be affected, clinicians should be aware of the broad range of clinical manifestations and symptoms and keep in mind that toxicities may occur late, at any point along a patient’s treatment course. Although the most common irAEs are rarely severe, some of them may be associated with great morbidity and even become life-threatening. The rate of occurrence, type and severity of irAEs may vary with the type of ICI; thus, grade 3 and 4 irAEs are reported in more than 55% of patients treated with the combination of ipilimumab 3 mg/kg and nivolumab 1 mg/kg.
Area covered: This review presents the management of irAEs resulting from checkpoint blockade, with a focus on rare irAEs.
Expert commentary: With the development of immuno-oncology and the expanding role of ICI, physicians have learnt to diagnose and treat most of the irAEs that can occur. This review provides an overview of current guidelines, previously published studies and our multidisciplinary team based practices. 相似文献
7.
8.
严桂英 《中国卫生标准管理》2020,(8):95-98
目的探究益气养精法对老年肺癌患者肿瘤标志物、生存期影响。方法研究纳入60例老年肺癌患者,均由本院2016年1月-2017年1月收治,采取随机数字表法将患者分为两组,对照组患者(30例)常规化疗治疗,观察组患者(30例)在化疗基础上联合益气养精法治疗,比较两组患者治疗效果、治疗前后癌胚抗原(carcino-embryonic antigen,CEA)及血清癌抗原125(serum oncoantigen 125,CA 125)肿瘤标志物水平、不良反应情况及患者2年生存率。结果观察组患治疗有效率高于对照组,P<0.05;治疗前,两组患者CEA及CA 125水平相当,P>0.05,治疗后均改善,观察组优于对照组,P<0.05;观察组患者不良反应与对照组相当,均较低,P>0.05;观察组患者2年生存率高于对照组,P<0.05。结论益气养精法治疗老年肺癌患者效果患者,患者症状改善,不良反应少,安全可靠,且患者2年生存率较高。 相似文献
9.